Colorectal Cancer Immunotherapy: Options and Strategies.

Szczegóły
Abstrakt

Tytuł:: Colorectal Cancer Immunotherapy: Options and Strategies.
Autorzy:: Johdi NA; UKM Medical Molecular Biology Institute (UMBI), National University of Malaysia, Bangi, Malaysia.
Sukor NF; UKM Medical Molecular Biology Institute (UMBI), National University of Malaysia, Bangi, Malaysia.
Źródło:: Frontiers in immunology [Front Immunol] 2020 Sep 18; Vol. 11, pp. 1624. Date of Electronic Publication: 2020 Sep 18 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms:: Disease Management*
Immunotherapy*/adverse effects
Immunotherapy*/methods
Colorectal Neoplasms/*immunology
Colorectal Neoplasms/*therapy
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor ; Cancer Vaccines ; Colorectal Neoplasms/pathology ; Combined Modality Therapy ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy, Adoptive ; Molecular Targeted Therapy/adverse effects ; Molecular Targeted Therapy/methods
References:: Front Immunol. 2019 Feb 05;10:128. (PMID: 30804938)
N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370)
Oncotarget. 2017 Jan 10;8(2):2171-2186. (PMID: 27974689)
Hum Gene Ther. 2002 Nov 1;13(16):1971-80. (PMID: 12427307)
Genomics. 1994 Oct;23(3):704-6. (PMID: 7851902)
J Oncol Pharm Pract. 2017 Jul;23(5):396-398. (PMID: 27122156)
Clin Cancer Res. 2011 Jul 1;17(13):4558-67. (PMID: 21558406)
Ann Oncol. 2016 Aug;27(8):1625-32. (PMID: 27287206)
Blood. 2014 Jul 10;124(2):188-95. (PMID: 24876563)
Br J Cancer. 2019 Jan;120(1):6-15. (PMID: 30413827)
Mol Ther. 2017 May 3;25(5):1248-1258. (PMID: 28366766)
Adv Immunol. 2014;122:91-128. (PMID: 24507156)
J Clin Oncol. 2015 Sep 1;33(25):2780-8. (PMID: 26014293)
J Clin Oncol. 2006 Jul 1;24(19):3089-94. (PMID: 16809734)
Immunol Rev. 2002 Oct;188:22-32. (PMID: 12445278)
Br J Cancer. 1973 Feb;27(2):99-105. (PMID: 4735112)
Prog Exp Tumor Res. 1970;13:1-27. (PMID: 4921480)
Nature. 1975 Aug 7;256(5517):495-7. (PMID: 1172191)
Curr Opin Immunol. 2013 Apr;25(2):214-21. (PMID: 23298609)
Anticancer Res. 2015 Jan;35(1):129-36. (PMID: 25550543)
N Engl J Med. 1988 Dec 22;319(25):1676-80. (PMID: 3264384)
Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4509-4517. (PMID: 30058685)
J Surg Oncol. 2014 Apr;109(5):440-4. (PMID: 24783267)
Expert Rev Vaccines. 2008 Sep;7(7):963-75. (PMID: 18767946)
Clin Cancer Res. 2000 Jun;6(6):2175-82. (PMID: 10873066)
Adv Cancer Res. 2014;121:67-124. (PMID: 24889529)
Front Immunol. 2019 Dec 17;10:2965. (PMID: 31921205)
J Biomed Sci. 2020 Jan 2;27(1):1. (PMID: 31894001)
Mol Ther. 2017 Jan 4;25(1):285-295. (PMID: 28129122)
J Clin Oncol. 2011 Mar 1;29(7):917-24. (PMID: 21282551)
Oncotarget. 2017 Dec 14;9(6):7204-7218. (PMID: 29467962)
Clin Cancer Res. 2008 Aug 1;14(15):4843-9. (PMID: 18676757)
J Clin Oncol. 2009 Dec 1;27(34):5763-71. (PMID: 19884534)
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. (PMID: 24277834)
Blood Adv. 2019 Jul 9;3(13):2022-2034. (PMID: 31289029)
Br J Haematol. 1992 Apr;80(4):466-71. (PMID: 1581231)
Clin Cancer Res. 2015 Feb 1;21(3):561-8. (PMID: 25424850)
Br J Cancer. 1994 May;69(5):899-902. (PMID: 8180020)
Int Immunol. 1996 May;8(5):765-72. (PMID: 8671665)
Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):89-96. (PMID: 29026920)
Ann Oncol. 2018 Jan 1;29(1):44-70. (PMID: 29155929)
BMJ Open. 2016 Dec 30;6(12):e013904. (PMID: 28039295)
J Immunol. 2002 Nov 15;169(10):5538-45. (PMID: 12421930)
Molecules. 2019 Mar 26;24(6):. (PMID: 30917623)
Genes Dev. 2018 Oct 1;32(19-20):1267-1284. (PMID: 30275043)
Mol Ther. 2011 Mar;19(3):620-6. (PMID: 21157437)
Int J Clin Exp Pathol. 2014 Jun 15;7(7):3918-27. (PMID: 25120768)
Nat Biotechnol. 2018 Mar 6;36(3):215-219. (PMID: 29509745)
Cancer Discov. 2016 Jan;6(1):80-95. (PMID: 26701088)
Ann Oncol. 2012 Oct;23(10):2479-2516. (PMID: 23012255)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
Oncotarget. 2017 Jul 22;8(40):68448-68459. (PMID: 28978129)
Clin Cancer Res. 2008 May 15;14(10):3060-9. (PMID: 18483372)
Sci Rep. 2019 Aug 12;9(1):11680. (PMID: 31406218)
Int J Biol Sci. 2019 Sep 7;15(12):2548-2560. (PMID: 31754328)
Nat Med. 2015 Aug;21(8):914-921. (PMID: 26193344)
J Immunother Cancer. 2018 Jan 23;6(1):8. (PMID: 29357948)
Ann Surg. 1891 Sep;14(3):199-220. (PMID: 17859590)
ESMO Open. 2017 May 2;2(2):e000150. (PMID: 28761741)
Am J Clin Oncol. 2016 Feb;39(1):98-106. (PMID: 26558876)
Mol Ther Oncolytics. 2018 Dec 13;12:41-48. (PMID: 30666318)
Mol Med Rep. 2018 Jan;17(1):465-473. (PMID: 29115580)
Front Immunol. 2019 Oct 11;10:2250. (PMID: 31681259)
Cancer. 1985 Aug 1;56(3):480-9. (PMID: 4005810)
Nat Rev Drug Discov. 2010 Apr;9(4):325-38. (PMID: 20305665)
Vaccine. 1997 Apr-May;15(6-7):759-68. (PMID: 9178479)
J Dermatol. 2016 Oct;43(10):1146-1153. (PMID: 27087489)
Mol Ther. 2018 Apr 4;26(4):986-995. (PMID: 29503195)
EXCLI J. 2018 Jan 22;17:159-168. (PMID: 29743854)
Blood. 2016 Sep 29;128(13):1688-700. (PMID: 27412889)
Blood. 1997 Sep 15;90(6):2188-95. (PMID: 9310469)
Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. (PMID: 30120708)
Vaccines (Basel). 2015 Jun 17;3(2):467-89. (PMID: 26343198)
Lancet. 1993 Feb 20;341(8843):457-60. (PMID: 8094488)
Clin Cancer Res. 2009 Feb 1;15(3):1086-95. (PMID: 19188184)
N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847)
BMC Cancer. 2018 Nov 12;18(1):1086. (PMID: 30415640)
Oncotarget. 2014 Dec 30;5(24):12472-508. (PMID: 25537519)
J Clin Oncol. 2017 Jan;35(1):124-125. (PMID: 27646950)
Clin Res Hepatol Gastroenterol. 2016 Apr;40(2):239-45. (PMID: 26516058)
Oncoimmunology. 2018 Feb 15;7(6):e1433982. (PMID: 29872569)
J Immunol. 2015 Aug 1;195(3):755-61. (PMID: 26188068)
Biochem J. 1996 Sep 1;318 ( Pt 2):361-77. (PMID: 8809021)
Blood. 2009 Jul 16;114(3):535-46. (PMID: 19451549)
Nat Rev Drug Discov. 2003 Jan;2(1):52-62. (PMID: 12509759)
Prostate. 2004 Aug 1;60(3):197-204. (PMID: 15176049)
Annu Rev Immunol. 2001;19:565-94. (PMID: 11244047)
J Clin Oncol. 2010 Mar 1;28(7):1099-105. (PMID: 20100959)
CA Cancer J Clin. 2017 May 6;67(3):177-193. (PMID: 28248415)
J Immunother. 2008 Oct;31(8):742-51. (PMID: 18779745)
Eur J Immunol. 1976 Jul;6(7):511-9. (PMID: 825377)
Pharmacotherapy. 2011 Aug;31(8):813-28. (PMID: 21923608)
Protein Eng. 1991 Oct;4(7):773-83. (PMID: 1798701)
CA Cancer J Clin. 2019 Sep;69(5):363-385. (PMID: 31184787)
J Clin Oncol. 2018 Jun 10;36(17):1658-1667. (PMID: 28981385)
J BUON. 2016 Jan-Feb;21(1):95-100. (PMID: 27061536)
Eur Urol. 2014 Oct;66(4):677-88. (PMID: 24674149)
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9. (PMID: 25190710)
Dev Biol Stand. 1992;77:229-31. (PMID: 1426667)
Cancer Res. 2007 Apr 15;67(8):3919-26. (PMID: 17440107)
J Clin Oncol. 2018 Mar 10;36(8):773-779. (PMID: 29355075)
Cancers (Basel). 2011 Jun 09;3(2):2554-96. (PMID: 24212823)
Mol Ther Oncolytics. 2016 Apr 20;3:16011. (PMID: 27626062)
Cell Discov. 2018 Nov 20;4:62. (PMID: 30479831)
Gut. 2017 Apr;66(4):683-691. (PMID: 26818619)
Clin Cancer Res. 2015 May 15;21(10):2268-77. (PMID: 25855804)
Hum Gene Ther. 2019 Apr;30(4):402-412. (PMID: 30693795)
PLoS One. 2014 Apr 10;9(4):e94281. (PMID: 24722266)
Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004. (PMID: 25717386)
J Leukoc Biol. 2013 Jul;94(1):25-39. (PMID: 23625198)
Front Immunol. 2019 May 08;10:911. (PMID: 31134056)
J Clin Oncol. 2019 May 1;37(13):1051-1061. (PMID: 30817251)
Annu Rev Immunol. 2011;29:235-71. (PMID: 21219185)
ILAR J. 2005;46(3):258-68. (PMID: 15953833)
J Exp Med. 1995 Aug 1;182(2):459-65. (PMID: 7543139)
Urol Oncol. 2016 Nov;34(11):484.e19-484.e25. (PMID: 27639776)
Eur J Immunol. 1975 Feb;5(2):117-21. (PMID: 1086218)
Cancer Res. 2007 Mar 15;67(6):2881-92. (PMID: 17363612)
Clin Cancer Res. 2015 Oct 1;21(19):4286-93. (PMID: 25977344)
Surg Gynecol Obstet. 1959 Aug;109(2):131-8. (PMID: 13675984)
Nature. 1967 Jun 3;214(5092):992-7. (PMID: 6055415)
Expert Opin Ther Targets. 2014 Dec;18(12):1407-20. (PMID: 25331677)
Science. 1985 Jun 14;228(4705):1315-7. (PMID: 4001944)
Oncoimmunology. 2014 Dec 13;3(9):e955684. (PMID: 25941618)
Iowa Orthop J. 2006;26:154-8. (PMID: 16789469)
Mol Ther Oncolytics. 2016 Jun 15;3:16015. (PMID: 27347557)
Cancer Res. 1960 Dec;20:1561-72. (PMID: 13756652)
N Engl J Med. 2019 Jan 3;380(1):45-56. (PMID: 30501490)
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419827090. (PMID: 30791740)
J Transl Med. 2006 Jan 03;4:1. (PMID: 16390546)
Hum Vaccin Immunother. 2014;10(11):3297-305. (PMID: 25483660)
Cancer Immunol Immunother. 2014 Mar;63(3):225-34. (PMID: 24327292)
Nat Immunol. 2002 Jul;3(7):611-8. (PMID: 12087419)
J Clin Oncol. 2019 Jan 1;37(1):33-43. (PMID: 30403572)
Blood Adv. 2019 Jul 23;3(14):2230-2236. (PMID: 31332046)
Methods Mol Biol. 2016;1403:755-61. (PMID: 27076165)
Cancer Immun. 2012;12:16. (PMID: 23390371)
Int J Clin Exp Pathol. 2011 Mar;4(3):295-306. (PMID: 21487525)
World J Gastroenterol. 2014 Apr 14;20(14):3738-50. (PMID: 24833840)
J Pathol. 1992 Dec;168(4):405-11. (PMID: 1484322)
Curr Top Microbiol Immunol. 2017;410:127-156. (PMID: 28900677)
Cancer Immunol Res. 2018 May;6(5):509-516. (PMID: 29615399)
Clin Cancer Res. 2016 Jun 15;22(12):3057-66. (PMID: 26763253)
Nature. 1987 Jul 16-22;328(6127):267-70. (PMID: 3496540)
Nature. 2017 May 24;545(7655):423-431. (PMID: 28541315)
J Natl Cancer Inst. 1993 Apr 21;85(8):622-32. (PMID: 8468720)
N Engl J Med. 2015 Apr 2;372(14):1324-32. (PMID: 25830422)
J Immunother. 2016 May;39(4):181-7. (PMID: 27070449)
JAMA Netw Open. 2019 Aug 2;2(8):e199249. (PMID: 31411714)
Lancet Oncol. 2017 Sep;18(9):1182-1191. (PMID: 28734759)
Ann Surg. 2013 Dec;258(6):879-86. (PMID: 23657083)
Nat Rev Cancer. 2012 Mar 22;12(4):278-87. (PMID: 22437872)
N Engl J Med. 2001 Dec 6;345(23):1655-9. (PMID: 11759643)
Cancer Immunol Immunother. 2019 Feb;68(2):247-256. (PMID: 30406375)
Br J Cancer. 2019 Aug;121(5):417-420. (PMID: 31353364)
Hematol Oncol Clin North Am. 2019 Apr;33(2):199-214. (PMID: 30832995)
J Immunother Cancer. 2017 Mar 21;5:22. (PMID: 28344808)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Ann Oncol. 2016 Aug;27(8):1386-422. (PMID: 27380959)
Methods Mol Biol. 2014;1060:139-48. (PMID: 24037840)
Clin Cancer Res. 2006 Nov 15;12(22):6737-47. (PMID: 17121894)
J Hematol Oncol. 2017 Apr 24;10(1):94. (PMID: 28434396)
Dis Colon Rectum. 2018 May;61(5):554-560. (PMID: 29624549)
Front Oncol. 2018 Mar 28;8:86. (PMID: 29644214)
N Engl J Med. 1991 Oct 24;325(17):1205-9. (PMID: 1922207)
Cell Rep. 2016 Apr 26;15(4):857-865. (PMID: 27149842)
J Immunother. 2013 Feb;36(2):133-51. (PMID: 23377668)
Science. 2006 Oct 6;314(5796):126-9. (PMID: 16946036)
Crit Rev Oncol Hematol. 2017 Jan;109:9-19. (PMID: 28010901)
Br J Cancer. 1992 Nov;66(5):850-5. (PMID: 1384643)
Asian Pac J Cancer Prev. 2011;12(8):2101-4. (PMID: 22292659)
N Engl J Med. 2010 Jul 29;363(5):411-22. (PMID: 20818862)
Oncology (Williston Park). 1995 Oct;9(10):947-52, 955, discussion 955-65. (PMID: 8573479)
Nature. 2002 Jan 31;415(6871):536-41. (PMID: 11823861)
Blood. 2013 Aug 8;122(6):863-71. (PMID: 23770775)
Curr Gastroenterol Rep. 2019 Jan 30;21(2):5. (PMID: 30701321)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Nat Immunol. 2001 Mar;2(3):261-8. (PMID: 11224527)
J Immunol. 2011 Mar 1;186(5):2772-9. (PMID: 21263073)
Semin Oncol. 2015 Aug;42(4):523-38. (PMID: 26320058)
N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92. (PMID: 18818309)
Expert Opin Biol Ther. 2011 Jul;11(7):855-73. (PMID: 21463133)
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15. (PMID: 17062687)
Br J Cancer. 2012 Oct 23;107(9):1525-33. (PMID: 22990653)
Int J Mol Sci. 2019 Mar 14;20(6):. (PMID: 30875739)
Clin Cancer Res. 2011 Jun 1;17(11):3520-6. (PMID: 21471425)
Curr Oncol. 2018 Oct;25(5):e373-e384. (PMID: 30464687)
Curr Treat Options Oncol. 2015 Jul;16(7):30. (PMID: 26031544)
Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67. (PMID: 13465720)
Blood. 2011 Jan 6;117(1):72-82. (PMID: 20889925)
Nat Immunol. 2013 Oct;14(10):1014-22. (PMID: 24048123)
Int J Cancer. 1973 May;11(3):765-73. (PMID: 4133950)
Am J Cancer Res. 2019 May 01;9(5):945-958. (PMID: 31218103)
J Exp Med. 1973 May 1;137(5):1142-62. (PMID: 4573839)
Proc R Soc Med. 1910;3(Surg Sect):1-48. (PMID: 19974799)
Cancer Res. 2006 Jun 1;66(11):5716-22. (PMID: 16740709)
Eur J Immunol. 2005 Jul;35(7):2081-8. (PMID: 15971272)
Int J Biol Markers. 2017 Oct 31;32(4):e415-e420. (PMID: 28604994)
PLoS One. 2014 Feb 24;9(2):e89263. (PMID: 24586641)
Eur J Immunol. 1975 Feb;5(2):112-7. (PMID: 1234049)
Immunotherapy. 2019 Jun;11(8):705-723. (PMID: 31045464)
Cancer Med. 2019 Aug;8(10):4753-4765. (PMID: 31237116)
Leuk Lymphoma. 2007 Mar;48(3):497-505. (PMID: 17454589)
Leukemia. 2004 Feb;18(2):309-15. (PMID: 14671645)
Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846. (PMID: 29420123)
Br Med Bull. 1964 May;20:154-8. (PMID: 14168097)
Contributed Indexing:: Keywords: FDA; T-cells; antibodies; colorectal carcinoma; cytokines; immunotherapy; treatments
Substance Nomenclature:: 0 (Antineoplastic Agents, Immunological)
0 (Biomarkers, Tumor)
0 (Cancer Vaccines)
0 (Immune Checkpoint Inhibitors)
Entry Date(s):: Date Created: 20201012 Date Completed: 20210419 Latest Revision: 20210419
Update Code:: 20240105
PubMed Central ID:: PMC7530194
DOI:: 10.3389/fimmu.2020.01624
PMID:: 33042104
: Czasopismo naukowe

Full Text Finder

Colorectal cancer is the third most common cancer in the world with increasing incidence and mortality rates globally. Standard treatments for colorectal cancer have always been surgery, chemotherapy and radiotherapy which may be used in combination to treat patients. However, these treatments have many side effects due to their non-specificity and cytotoxicity toward any cells including normal cells that are growing and dividing. Furthermore, many patients succumb to relapse even after a series of treatments. Thus, it is crucial to have more alternative and effective treatments to treat CRC patients. Immunotherapy is one of the new alternatives in cancer treatment. The strategy is to utilize patients' own immune systems in combating the cancer cells. Cancer immunotherapy overcomes the issue of specificity which is the major problem in chemotherapy and radiotherapy. The normal cells with no cancer antigens are not affected. The outcomes of some cancer immunotherapy have been astonishing in some cases, but some which rely on the status of patients' own immune systems are not. Those patients who responded well to cancer immunotherapy have a better prognostic and better quality of life.
(Copyright © 2020 Johdi and Sukor.)

Informacja